Loading
companiesCompany
photonamic
photonamic is the small German company behind Gliolan (Gleolan), the drink of 5-aminolevulinic acid that makes glioma tissue glow pink under a surgical microscope so neurosurgeons can remove more of the tumour.
Also called: photonamic GmbH & Co. KGPhotonamic
Overview
photonamic GmbH & Co. KG, founded in 2002 in Wedel near Hamburg, developed oral 5-aminolevulinic acid (Gliolan in Europe, Gleolan in the United States) for fluorescence-guided resection of high-grade glioma. Malignant glioma cells convert the drug into fluorescent protoporphyrin IX, and the randomised trial that led to European approval in 2007 showed more complete resections and longer progression-free survival; FDA approval followed in 2017 through its partner NX Development Corp. It leads phase 3 trials extending the approach, registered on ClinicalTrials.gov.
Headquarters
Wedel, DE
Scorecard
All companies#97of 1244 companies, score 51
- approved products +12
- modalities +4
- regions +5
- registry trials +30
2 approved, 0 in phase 3, 0 earlier, 0 targets, 264 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Founded
2002
ApprovedTopical porphyrin precursor for photodynamic therapy
Aminolevulinic acid (topical, for photodynamic therapy) · Levulan Kerastick / Ameluz
Aminolevulinic acid is painted on sun-damaged skin and then activated with a lamp, destroying actinic keratoses before they can become skin cancer; in Europe the gel is also approved for superficial basal cell carcinoma.
ApprovedFluorescence-guided surgery agent (protoporphyrin IX precursor)
5-Aminolevulinic acid (oral, for glioma surgery) · Gleolan / Gliolan
A drink taken before brain surgery that makes high-grade glioma glow under blue light, letting surgeons remove more tumour safely.
Similar pages
- CompanySBI Pharmaceuticals
Shares Aminolevulinic acid (topical, for photodynamic therapy), Fluorescence-guided surgery, Pivotal (registrational) trial, Clinical trial.
- TrialGleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Shares 5-Aminolevulinic acid (oral, for glioma surgery), Fluorescence-guided surgery.
- CompanyDenovo Biopharma
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
- CompanyBlaze Bioscience
Shares Fluorescence-guided surgery, Pivotal (registrational) trial, Clinical trial.
- TrialA Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
Shares Aminolevulinic acid (topical, for photodynamic therapy), Glioma & glioblastoma.
- TrialAdjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Shares Aminolevulinic acid (topical, for photodynamic therapy), Glioma & glioblastoma.
- CompanyPregLem
- CompanyDiffusion Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
cancers
technologies
drugs
ApprovedFluorescence-guided surgery agent (protoporphyrin IX precursor)
5-Aminolevulinic acid (oral, for glioma surgery) · Gleolan / Gliolan
ApprovedTopical porphyrin precursor for photodynamic therapy
Aminolevulinic acid (topical, for photodynamic therapy) · Levulan Kerastick / Ameluz